

Screening of Childhood Latent Tuberculosis Infection by an Interferon Gamma Release Assay

Thesis

Submitted for partial fulfillment of M.Sc. Degree in **Pediatrics**

By

Ahmed Reda M. Hassan

M.B., B.Ch (2006)

Under Supervision of

Professor / Eman Mahmoud Fouda

Professor of Pediatrics

Faculty of Medicine, Ain Shams University

Professor / Maha Muhmmad Fathy

Professor of Medical Microbiology & Immunology

Faculty of Medicine, Ain Shams University

Doctor/ Terez Boshra Kamel

Assistant Professor of Pediatrics

Faculty of Medicine, Ain Shams University

**Faculty of Medicine
Ain Shams University**

2014

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَقُلْ اَعْمَلُوا فَسَيَرَى اللَّهُ عَمَلَكُمْ
وَرَسُولُهُ وَالْمُؤْمِنُونَ

صدق الله العظيم

سورة التوبة آية (١٠٥)



Acknowledgement

*First, thanks are all due to **Allah** for Blessing this work until it has reached its end, as a part of his generous help throughout our life.*

*I would like to express my deep thanks to **Professor Dr. Eman Mahmoud Fouda**, professor of Pediatrics, faculty of medicine, Ain Shams University, for her continuous encouragement and support during every step of this work,*

*I wish to express my sincere gratitude and respect to **Professor Dr. Maha Mohamed Fathy**, professor of Microbiology & Immunology, Ain Shams University for her valuable advice in this study.*

*I am deeply grateful to **Dr. Terez Boshra Kamel**, Assistant Professor of Pediatrics, Ain Shams University for her great help and advice in writing every Word of this study.*

Last but not least, I would like to thank these children and their parents who shared in my thesis.



Ahmed Reda M. Hassan

List of Contents

	Page
Acknowledgment	--
List of Abbreviations	i
List of Figures	ii
List of Tables	v
 Introduction and Aim of the Work	 1
 Review of Literature	 4
Tuberculosis	4
▪ Introduction	4
▪ Global Epidemiology of Tuberculosis	4
▪ Tuberculosis in Egypt	6
▪ Mycobacterium tuberculosis	7
▪ Clinical picture of tuberculosis	9
▪ Transmission of M. tuberculosis	10
▪ Pathogenesis of tuberculosis	11
▪ Immune response to M. tuberculosis	13
 Latent tuberculosis	 15
▪ T-cells (types)	15
▪ Mechanisms of host and bacillus that contribute to persistent infection (Latent tuberculosis)	17
 Fate of TB infection	 24
Clinical diagnosis of tuberculosis	26
▪ Risk factors	26
▪ Types (pulmonary & extrapulmonary)	26
▪ Perinatal tuberculosis	32
 Investigation for tuberculosis	 34
▪ Laboratory diagnosis of TB	34
▪ Radiological diagnosis of TB	36

List of Contents (Cont.)

	Page
Tuberculin skin test	37
Interferon-gamma assays	42
▪ Types of the assays	45
▪ QuantiFERON (QFT) test	48
▪ T-SPOT TB test	52
Treatment of tuberculosis	53
Prophylaxis against tuberculosis	59
Patients and Methods	63
Results	72
Discussion	95
Summary and Conclusion	103
Recommendations	107
References	108
Arabic Summary	--

List of Abbreviations

AAP	American Academy of Pediatrics
AIDS	Acquired immune deficiency syndrome
BCG	Bacilli –Calmette –Guerin
CFP-10	Culture filtrate protein
DOTS	Direct observed therapy
ELISA	Enzyme linked immune sorbent assay
EMB	Ethambutol
ESAT-6	Early secretory antigen target-6
ETH	Ethionamide
FK	Fructokinase
HEPA	High –efficiency particular air
HIV	Human immunodeficiency virus
HLA	Human leukocyte antigen
IGRA	Immunoglobulin release assay
IL2	Interleukin 2
INF-γ	Interferon –gamma
INH	Isoniazid
LTBI	Latent tuberculosis infection
MDR	Multidrug resistant
MHC	Major histocompatibility complex
MW	Molecular weight
NOS2	Nitric oxide synthase
NRAMP	Natural resistance –associated macrophage protein
PCR	Polymerase chain reaction
PPD	Protein purified derivative
PZA	Pyrazinamide
QFT	Quantiferon-test
QFT-G	Quantiferon –TB –gold
RD-1	Region of difference -1
RMP	Rifampicin
RNI	Reactive nitrogen intermediate
ROI	Reactive oxygen intermediate

List of Abbreviations (Cont.)

SM	Streptomycin
SODA	Superoxide dismutase A
TB	Tuberculosis
TGF	Transforming growth factor
TH	T –helper
TLR	Toll - like receptor
TNF	Tumor necrosis factor
TST	Tuberculin skin test
UK	United kingdom
WBC	White blood cells
WHO	World health organization

List of Tables

Table	Title	Page
(1)	Systemic and pulmonary manifestations of active TB.	27
(2)	Clinical manifestations and pathology of extra pulmonary TB.	30
(3)	Size of induration area from a mantoux TST result considered positive in children.	40
(4)	The advantages of interferon-gamma tests over TST.	44
(5)	Characteristics of tests of latent tuberculosis infection with regard to test administration.	47
(6)	The most commonly used antituberculous drugs	53
(7)	Drugs for treatment of drug-resistant tuberculosis in children.	54
(8)	Common adverse reactions and recommended monitoring of antituberculous medications.	55
(9)	Interpretation of QuantiFERON –TB Gold In-Tube results.	70
(10)	Demographic Data of the latent TB cases.	72
(11)	Age distribution of the latent TB group (+ve TST) & -ve TST group.	72
(12)	Sex distribution of the latent TB group (+ve TST) & -ve TST group.	72
(13)	Frequency of Wt & Ht centile among the studied latent TB cases.	73
(14)	Routine blood tests results of the studied latent TB cases.	73
(15)	Types of the TB source related to the studied latent TB children.	74
(16)	Clinical Data of the studied latent TB cases.	74
(17)	The interpretation of the Quantiferon test among latent TB children.	74

List of Tables (Cont.)

Table	Title	Page
(18)	The interpretation of the Quantiferon test among -ve TST group.	74
(19)	Statistical comparison between latent TB group (+ve TST) & -ve TST group as regards sex, age groups & type of TB of contact's case.	75
(20)	Statistical comparison between latent TB group (+ve TST) & -ve TST group as regards crowding index & duration of contact's exposure to the diseased case.	76
(21)	Statistical comparison between latent TB group (+ve TST) & -ve TST group as regards Quantiferon test results.	76
(22)	Statistical comparison between +ve & -ve Quantiferon results as regards Sex, Ages groups & crowding index of latent TB cases.	77
(23)	Statistical comparison between +ve & -ve Quantiferon results as regards Ht Centile & Wt Centile of latent TB cases.	79
(24)	Statistical comparison between +ve & -ve Quantiferon results as regards CBC results, ESR 1st hr of latent TB cases.	79
(25)	Statistical comparison between +ve & -ve Quantiferon results of latent TB cases as regards duration of contact's exposure to the diseased case, induration area of TST, presence of BCG scar & type of TB of the contact's case.	81
(26)	Statistical comparison between males and females patients as regards age and crowding Index of latent TB cases.	83

List of Tables (Cont.)

Table	Title	Page
(27)	Statistical comparison between males and females patients as regards Wt &Ht Centile of latent TB cases.	83
(28)	Statistical comparison between males and females patients as regards CBC results & ESR 1st hr of latent TB cases.	84
(29)	Statistical comparison between males and females patients of latent TB cases as regards duration of contact's exposure to the diseased case, Induration area of TST, Presence of BCG scar &Type of TB of the contact's case.	84
(30)	Statistical comparison between males and females patients of latent TB cases as regards Quantiferon test results.	85
(31)	Statistical comparison between (< 6 yrs old) group & (≥ 6yrs old) group as regards sex & crowding index of latent TB cases.	86
(32)	Statistical comparison between (< 6 yrs old) group & (≥ 6yrs old) group as regards Wt Centile & Ht Centile of latent TB cases.	87
(33)	Statistical comparison between (< 6 yrs old) group & (≥ 6yrs old) group as regards CBC results & ESR 1st hr of latent TB cases.	88
(34)	Statistical comparison between (< 6 yrs old) group & (≥ 6yrs old) group of latent TB cases as regards duration of contact's exposure to the diseased case, induration area of TST, presence of BCG scar &type of TB of the contact's case.	88
(35)	Statistical comparison between (< 6 yrs old) group & (≥ 6yrs old) group of latent TB cases as regards Tuberculin test results & Quantiferon results.	91

List of Tables (Cont.)

Table	Title	Page
(36)	Correlation between Quantiferon test result and duration of contact's exposure to the diseased case, crowding Index, sex, age, WBCs & type of TB disease of the contact's cases as predictors for positive Quantiferon test result.	92
(37)	Distribution of concordant & discordant results for Quantiferon test & tuberculin test among contacts cases to the open TB cases.	93
(38)	Over all agreement between Quantiferon test and tuberculin skin test for children contacts of TB cases.	93

List of Figures

Fig.	Title	Page
(1)	Tuberculosis-prevalence-WHO-2009.	5
(2)	Schematic representation of the mycobacterial cell wall.	7
(3)	Acid-fast stain of mycobacterium.	8
(4)	Transmission of M. tuberculosis.	10
(5)	Immune response to M. tuberculosis.	13
(6)	Immune response to M. tuberculosis.	14
(7)	Types of T-cells in latent tuberculosis.	15
(8)	Macrophage antimycobacterial mechanisms.	18
(9)	Phagocytosis action of the macrophage.	19
(10)	Production of antimicrobial intermediates RNI &ROI.	19
(11)	The principles of immune reaction to TB infection.	21
(12)	Humoral and cellular immunity in TB infection.	22
(13)	The interaction between M. tuberculosis and MHC II cells.	23
(14)	Symptoms of tuberculosis.	28
(15)	Chest x ray show caseous foci with cavity formation.	29
(16)	Fate of pulmonary TB infection.	29
(17)	Some radiographic findings of pulmonary TB.	37
(18)	Skin inoculation of tuberculin PPD.	39
(19)	Measurement of the induration area.	40
(20)	The action of gamma interferon.	43
(21)	Summary of the QuantiFERON-TB GOLD test	49
(22)	Mechanism of action of drugs on mycobacterium tuberculosis.	55
(23)	Inoculation and interpretation of Tuberculin skin test.	66
(24)	The package of the Quantiferon –TB gold used in our study.	67
(25)	The results of IGRA titer in our Quantiferon test.	69

List of Figures

Fig.	Title	Page
(26)	Sex distribution of latent TB group (+ve TST) & -ve TST group.	73
(27)	Statistical comparison between latent TB group (+ve TST) & -ve TST group as regards type of TB of contact's case.	75
(28)	Statistical comparison between latent TB group (+ve TST) & -ve TST group as regards Quantiferon test results.	77
(29)	Statistical comparison between +ve & -ve Quantiferon results as regards sex.	78
(30)	Statistical comparison between +ve & -ve Quantiferon results as regards crowding index.	78
(31)	Statistical comparison between +ve & -ve Quantiferon results as regards WBC counts.	80
(32)	Statistical comparison between +ve & -ve Quantiferon results as regards duration of contact's exposure to the diseased case.	82
(33)	Statistical comparison between +ve & -ve Quantiferon results as regards type of TB of the contact's case.	82
(34)	Statistical comparison between males and females patients as regards the duration of the contact's exposure to the TB case.	85
(35)	Statistical comparison between males and females patients as regards Quantiferon results.	86
(36)	Statistical comparison between (< 6 yrs old) group & (\geq 6yrs old) group as regards crowding index.	87
(37)	Statistical comparison between (< 6 yrs old) group & (\geq 6yrs old) group as regards duration of contact's exposure to the diseased case.	89

List of Figures

Fig.	Title	Page
(38)	Statistical comparison between (< 6 yrs old) group & (\geq 6yrs old) group as regards type of TB of the contact's case.	90
(39)	Statistical comparison between (< 6 yrs old) group & (\geq 6yrs old) group as regards Quantiferon test results.	91
(40)	Statistical comparison and percentage of Quantiferon results among all contacts to open TB cases whither with positive or negative tuberculin skin test results.	94

Introduction

Tuberculosis (TB) remains a global public health problem, with an estimated 3 million deaths and 8 million new cases yearly. Most individuals infected with *Mycobacterium tuberculosis* control the bacilli and develop asymptomatic latent infection, a reservoir currently estimated to be one-third of the total human population (*Goswami et al., 2009*).

Latently infected individuals face a lifetime risk of reactivation with symptomatic TB disease depending upon their immune status. There is a dramatic increase in the risk of developing reactivation TB in Immunocompromised children or children with deficient immune system (patients receiving steroids for long periods) which had become increasingly common. So, there is an urgent need for more efficient ways of diagnosing latent TB (*Pai et al., 2008*).

The tuberculin skin test (TST) has long been used as a gold standard for the diagnosis of latent TB. TST is a measure of a delayed type hypersensitivity response to purified protein derivative (PPD). PPD is a mixture of mycobacterial antigens, some of which are shared between non tuberculous mycobacteria (NTM) and *Mycobacterium bovis* Bacille Calmette-Guerin (BCG) vaccine strains (*Van Zyl-Smit et al., 2009*).

As a result, the TST is not adequate for the diagnosis of latent TB in populations with high BCG coverage and/or high levels of NTM exposure (*Pai et al., 2008*).

The sensitivity also may be low in individuals with decreased immune function (i.e., AIDS and other immunosuppressive conditions, advanced TB, malnutrition). To increase the specificity of such tests, 2 M. tuberculosis-